Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian Women

Canadian Journal of Public Health

Volumn 101, Issue 5, 2010, Pages 405-409

  Neutel, C Ineke ^a   Morrison, Howard ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Alcohol; Breast cancer incidence; Hormone replacement therapy; Obesity; Physical activity; Population attributable risk

Indexed keywords

AGED; ARTICLE; BREAST TUMOR; CANADA; FEMALE; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MIDDLE AGED; RISK FACTOR; STATISTICS;

AGED; BREAST NEOPLASMS; CANADA; FEMALE; HEALTH SURVEYS; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; RISK FACTORS;

EID: 79952232616     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03404862     Document Type: Article

References (33)

1. Nelson HD. Menopause. Lancet 2008;371(9614):760-70.
2. Canderelli R, Leccesse LA, Miller NL. Benefits of hormone replacement therapy in post menopausal women. J Am Acad Nurse Pract 2007;19:635-41.
3. Bhavnani BR, Strickler RC. Menopausal hormone therapy. J Obstet Gynaecol Can 2005;27(2):137-62.
4. Rosano GM, Panina G. Cardiovascular pharmacology of hormone replacement therapy. Drugs Aging 1999;15:219-34.
5. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: Scientific review. JAMA 2002;288:872-81.
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
7. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
8. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
9. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008;188:641-44.
10. Coombs N, Taylor R, Wilcken N, Boyages J. HRT and breast cancer: Impact on population risk and incidence. Eur J Cancer 2005;41:1775-81.
11. Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 2007;16:17-27.
12. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics, 2008. Toronto, ON, 2008.
13. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-74.
14. Clarke CA, Glaser SL. Declines in breast cancer after the WHI: Apparent impact of hormone therapy. Cancer Causes Control 2007;18:847-52.
15. Beral V, Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003;362:419-27.
16. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 2004;112:130-34.
17. Krieger N. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: Critical reflections. Int J Epidemiol 2008;37:627-37.
18. Banks E, Canfell K, Reeves G. HRT and breast cancer: Recent findings in the context of the evidence to date. Women's Health 2008;4:427-31.
19. Collishaw NE, Boyd NF, Cantor KP, Hammond SK, Johnson KC, Millar J, et al. Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk. Toronto, ON: Ontario Tobacco Research Unit, OTRU Special Report Series, April 2009.
20. Ewertz M, Mellemkjaer L, Poulsen AH, Friis S, Sorensen HT, Pedersen L, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005;92:1293-97.
21. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-27.
22. Sprague BL, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol 2008;168:404-11.
23. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR. The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65-79 years of age. Cancer Epidemiol Biomarkers Prev 2003;12:1061-66.
24. Longnecker MP. Re: "Point/counterpoint: meta-analysis of observational studies". Am J Epidemiol 1995;142:779-82.
25. Li CI, Malone KE, Daling JR. The relationship between various measures of cigarette smoking and risk of breast cancer among older women 65-79 years of age (United States). Cancer Causes Control 2005;16:975-85.
26. Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives-The Norwegian Women and Cancer study. Int J Cancer 2007;121:645-48.
27. Friedenreich CM, Bryant HE, Courneya KS. Case-control study of lifetime physical activity and breast cancer risk. Am J Epidemiol 2001;154:336-47.
28. Lahmann PH, Friedenreich C, Schuit AJ, Salvini S, Allen NE, Key TJ, et al. Physical activity and breast cancer risk: The European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007;16:36-42.
29. Breslow NE, Day NE. Statistical Methods in Cancer Research Volume I - the Analysis of Case-control Studies. Lyon, France: IARC Scientific Publications No.32, 1980;74-76.
30. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985;122:904-14.
31. Clarke CA, Purdie DM, Glaser SL. Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer 2006;6:170.
32. Colditz GA. Decline in breast cancer incidence due to removal of promoter: Combination estrogen plus progestin. Breast Cancer Research 2007;9(4):108. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206710/?tool=pubmed (Accessed August 5, 2010).
33. Banks E, Beral V, Cameron R, Hogg A, Langley N, Barnes I, et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 2001;6:357-63.